Stephanie Barbanell

Associate
Stephanie Barbanell
New York
+1 212 459 7436
Stephanie Barbanell is an associate in the firm’s Business Law department and a member of its Technology group, and Public M&A/Corporate governance practice.

Professional Experience

Her recent M&A experience includes representing:

  • Orchard Therapeutics in its sale to Kyowa Kirin
  • EQRx in its sale to Revolution Medicines in an all-stock transaction intended to add more than $1 billion in net cash to Revolution Medicines’ balance sheet
  • Magenta Therapeutics in its reverse merger with Dianthus Therapeutics
  • Intapp in its acquisition of Paragon Data Labs
  • TCR2 in its cross-border all-stock combination with Adaptimmune
  • Frazier Lifesciences Acquisition Corporation in its business combination with NewAmsterdam Pharma
  • Forma Therapeutics in its $1.1 billion sale to Novo Nordisk
  • KVH Industries in its $55 million sale of its inertial navigation business to EMCORE
  • SYLVAIN in its sale to kyu
  • BioDelivery Sciences International in its $605 million sale to Collegium Pharmaceutical
  • Retail Properties of America in its $7.5 billion sale to Kite Realty Group Trust
  • Leaf Group in its $323 million sale to Graham Holdings Company
  • Special Committee of NantKwest in NantKwest’s merger with ImmunityBio
  • MyoKardia in connection with its $13.1 billion sale to Bristol-Myers Squibb Company
  • Xeris in in its cross-border acquisition of Strongbridge Biopharma for stock and CVRs valued at $267 million

Areas of Practice

Credentials

Education

JD2020

Georgetown University Law Center

BSBAMarketing2017

University of Florida

Admissions

Bars

  • New York

Recognition & Awards

While attending Georgetown Law, Stephanie was on the Environmental Law Journal.